JP2023551943A - うつ病の処置のためのｎｒ２ｂ－ｎｍｄａ受容体ｎａｍについての投薬レジメン - Google Patents

うつ病の処置のためのｎｒ２ｂ－ｎｍｄａ受容体ｎａｍについての投薬レジメン Download PDF

Info

Publication number
JP2023551943A
JP2023551943A JP2023533801A JP2023533801A JP2023551943A JP 2023551943 A JP2023551943 A JP 2023551943A JP 2023533801 A JP2023533801 A JP 2023533801A JP 2023533801 A JP2023533801 A JP 2023533801A JP 2023551943 A JP2023551943 A JP 2023551943A
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
compound
acceptable salt
treatment
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023533801A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023551943A5 (https=
Inventor
チャ，ジャン－ホ
ファーラー，トーマス
ゴメズ－マンシラ，バルタザール
パパニコロウ，ディミトリス
セルバン，カーメン－ガブリエラ
ライソン，フロリアン ボン
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2023551943A publication Critical patent/JP2023551943A/ja
Publication of JP2023551943A5 publication Critical patent/JP2023551943A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023533801A 2020-12-04 2021-12-03 うつ病の処置のためのｎｒ２ｂ－ｎｍｄａ受容体ｎａｍについての投薬レジメン Pending JP2023551943A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063121513P 2020-12-04 2020-12-04
US202063121508P 2020-12-04 2020-12-04
US63/121,513 2020-12-04
US63/121,508 2020-12-04
PCT/IB2021/061268 WO2022118264A1 (en) 2020-12-04 2021-12-03 Dosage regimen for a nr2b-nmda receptor nam for the treatment of depression

Publications (2)

Publication Number Publication Date
JP2023551943A true JP2023551943A (ja) 2023-12-13
JP2023551943A5 JP2023551943A5 (https=) 2024-12-10

Family

ID=78844691

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023533801A Pending JP2023551943A (ja) 2020-12-04 2021-12-03 うつ病の処置のためのｎｒ２ｂ－ｎｍｄａ受容体ｎａｍについての投薬レジメン

Country Status (10)

Country Link
US (1) US20240041853A1 (https=)
EP (1) EP4255419A1 (https=)
JP (1) JP2023551943A (https=)
KR (1) KR20230116865A (https=)
AU (1) AU2021390209A1 (https=)
CA (1) CA3203144A1 (https=)
IL (1) IL303357A (https=)
MX (1) MX2023006567A (https=)
TW (1) TW202237103A (https=)
WO (1) WO2022118264A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3258070A1 (en) * 2022-06-02 2023-12-07 Novartis Ag SUBCUTANEOUS ADMINISTRATION OF ONFASPRODIL AND DOSING METHODS INTENDED FOR USE IN THE TREATMENT OF DEPRESSIVE DISORDERS
TW202539663A (zh) * 2023-12-06 2025-10-16 瑞士商諾華公司 用於治療抑鬱障礙之組成物和方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002161052A (ja) * 2000-10-02 2002-06-04 Pfizer Prod Inc 治療用のｎｍｄａｎｒ２ｂアンタゴニスト
JP2017528502A (ja) * 2014-09-26 2017-09-28 カデント セラピューティクス，インコーポレーテッド ＮＲ２ＢのＮ−アルキルアリール−５−オキシアリール−オクタヒドロ−シクロペンタ［ｃ］ピロールネガティブアロステリックモジュレーター
JP2018506514A (ja) * 2014-12-23 2018-03-08 セレコー，インコーポレイテッド 化合物、組成物および方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR097794A1 (es) * 2013-09-26 2016-04-13 Mnemosyne Pharmaceuticals Inc Moduladores octahidro-ciclopenta[c]pirrol negativos de nr2b
BR112018007181A2 (pt) * 2015-10-14 2018-10-16 Bristol-Myers Squibb Company antagonistas de nr2b seletivos
KR20180063306A (ko) * 2015-10-14 2018-06-11 브리스톨-마이어스 스큅 컴퍼니 선택적 nr2b 길항제

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002161052A (ja) * 2000-10-02 2002-06-04 Pfizer Prod Inc 治療用のｎｍｄａｎｒ２ｂアンタゴニスト
JP2017528502A (ja) * 2014-09-26 2017-09-28 カデント セラピューティクス，インコーポレーテッド ＮＲ２ＢのＮ−アルキルアリール−５−オキシアリール−オクタヒドロ−シクロペンタ［ｃ］ピロールネガティブアロステリックモジュレーター
JP2018506514A (ja) * 2014-12-23 2018-03-08 セレコー，インコーポレイテッド 化合物、組成物および方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Proof of Concept Study Evaluating the Efficacy and Safety of MIJ821 in Patients With Treatment-resis", CLINICALTRIALS, JPN7025004645, pages 03756129, ISSN: 0005717889 *

Also Published As

Publication number Publication date
MX2023006567A (es) 2023-06-16
US20240041853A1 (en) 2024-02-08
CA3203144A1 (en) 2022-06-09
KR20230116865A (ko) 2023-08-04
AU2021390209A9 (en) 2024-10-31
IL303357A (en) 2023-08-01
TW202237103A (zh) 2022-10-01
EP4255419A1 (en) 2023-10-11
WO2022118264A1 (en) 2022-06-09
AU2021390209A1 (en) 2023-06-22

Similar Documents

Publication Publication Date Title
EP4114466B1 (en) Treatment of pain and vasoconstriction
US20200113882A1 (en) Use of 4-Aminopyridine to Improve Neuro-Cognitive and/or Neuro-Psychiatric Impairment in Patients with Demyelinating and Other Nervous System Conditions
CA2899602C (en) Pharmaceutical uses of inorganic nitrites
US20240366582A1 (en) Treatment of raynaud's disease
JP2023551943A (ja) うつ病の処置のためのｎｒ２ｂ－ｎｍｄａ受容体ｎａｍについての投薬レジメン
JP2022546456A (ja) 自殺傾向を含む大うつ病性障害を有する患者の治療のためのエスケタミン
CN116744922A (zh) Nr2b-nmda受体nam在治疗抑郁症中的剂量方案
US20230372364A1 (en) Method of treating gaba mediated disorders
WO2024196957A1 (en) Method for treating l-dopa-induced dyskinesia using befiradol
TW202440106A (zh) 用於治療勃起障礙之化合物
JP2024518455A5 (https=)
EA046106B1 (ru) ПРИМЕНЕНИЕ АНТАГОНИСТА mGluR5 ДЛЯ ЛЕЧЕНИЯ ТОЛЕРАНТНОСТИ К ОПИОИДНЫМ АНАЛЬГЕТИКАМ

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241202

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241202

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251022

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251028

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260421